8-K: Milestone Pharmaceuticals Plans Etripamil NDA Resubmission Following FDA Feedback

Milestone Pharmaceuticals plans to resubmit its New Drug Application for etripamil nasal spray in the second quarter of 2024 after receiving feedback from the FDA.

Summary

• Milestone Pharmaceuticals is planning to resubmit its New Drug Application (NDA) for etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) to the FDA.
• This decision follows a Type A meeting with the FDA where the agency provided feedback on the previously submitted NDA, which had received a Refusal to File letter.
• The FDA indicated that the timing of adverse events had minimal impact on the safety profile of etripamil.
• Milestone will restructure data sets and reformat certain files to align with the FDA's guidance.
• The company expects a standard NDA review period after the resubmission, which is planned for the second quarter of 2024.
• Milestone has implemented cash conservation measures, including program deferrals and team restructuring, to extend its operating runway into mid-2025.
• The company anticipates a $75 million payment upon FDA approval of etripamil, which will be used to fund the commercial launch.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the plan to resubmit the NDA and the extended cash runway, but there are still risks associated with regulatory approval and the need for cost-saving measures.

Positives

• The FDA has not requested additional clinical trials, which could have been costly and time-consuming.
• The company has extended its cash runway into mid-2025, providing financial stability.
• The potential $75 million payment upon approval will fund the commercial launch of etripamil.
• Etripamil is designed for self-administration, offering patients a convenient treatment option.
• The FDA feedback suggests that the safety profile of etripamil is not a major concern.

Negatives

• The company had to restructure data sets and reformat files, indicating issues with the initial NDA submission.
• The company has implemented cash conservation measures, including program deferrals and team restructuring, which may impact operations.
• The resubmission of the NDA means a delay in the potential approval of etripamil.

Risks

• There is no guarantee that the resubmitted NDA will be approved by the FDA.
• The FDA may require additional trials or data, which could further delay approval.
• The company's financial stability is dependent on the $75 million payment upon approval.
• The company is subject to general economic, political, and market conditions, which could impact its operations.
• The company is subject to risks related to pandemics and public health emergencies.

Future Outlook

The company plans to resubmit the NDA for etripamil in the second quarter of 2024 and expects a standard review period. They anticipate a $75 million payment upon approval to fund the commercial launch and expect their current cash to fund operations into mid-2025.

Management Comments

• Joseph Oliveto, President and CEO, stated that the company thanks the FDA for its thoughtful consideration and direction on the NDA resubmission.
• Management believes that etripamil has the potential to be a valuable new option for patients with PSVT and may establish a new standard of care.

Industry Context

This announcement is relevant to the cardiovascular pharmaceutical industry, particularly companies developing treatments for arrhythmias. The successful approval of etripamil could provide a new treatment option for patients with PSVT, a condition with limited effective treatment options.

Comparison to Industry Standards

• The standard NDA review period is typically 10-12 months, which is what Milestone is expecting after resubmission.
• Other companies developing treatments for PSVT include companies like BioMarin Pharmaceutical and Corvia Medical, but they are using different approaches such as gene therapy and interatrial shunt devices.
• The self-administered nasal spray approach of etripamil is unique compared to other treatments that often require medical supervision or invasive procedures.

Stakeholder Impact

• Shareholders may see a positive impact if the NDA is approved and etripamil is successfully commercialized.
• Patients with PSVT may benefit from a new self-administered treatment option.
• Healthcare providers may have a new tool to manage PSVT patients.

Next Steps

• Milestone will restructure data sets and reformat files to align with FDA guidance.
• The company will resubmit the NDA for etripamil in the second quarter of 2024.
• Milestone will continue to work with the FDA to bring etripamil to market.

Key Dates

Keywords

etripamil, PSVT, FDA, NDA, resubmission, cardiovascular, pharmaceutical, nasal spray, arrhythmia, clinical trial